Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Narjes

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Circulation|August 19, 1997
Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in menT H Müller, H Weisenberger, R Brickl, et al.
European Journal of Clinical Pharmacology|January 1, 1981
A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tabletW H Aellig, H H Narjes, E Nüesch, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Circulation|August 19, 1997
Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in menT H Müller, H Weisenberger, R Brickl, et al.
European Journal of Clinical Pharmacology|January 1, 1981
A pharmacodynamic and pharmacokinetic comparison of pindolol 20 mg retard and a conventional tabletW H Aellig, H H Narjes, E Nüesch, et al.
Pageof 2